Clinical Trials

  •  
    • Phase I (late) – USFDA submission 
      NCE for Type II diabetes patients conducted in-house
  •  
    • Phase II – USFDA submission 
      NDDS formulation for patients infested with head Lice conducted in-house
  •  
    Phase II-A – Australian TGA submission
    NCE for patients infested with head Lice conducted in-house
  •  
    Phase I – DCGI and USFDA submission 
    NDDS formulation for breast cancer patients onducted at 5 sites (hospitals) 
  •  
    Phase III – USFDA submission
    Dermatology (patients with Tenia Pedis)